Associated Papers
Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy.
Gomez-Almeria M et al.
Neuropharmacology, 2026
TDP-43 in neurodegeneration and cancer: Decoding the mechanism of mRNA localization and translation.
Pang P et al.
Biochemistry and Biophysics Reports, 2026
Elucidation of Molecular Mechanisms of Lipid-Altered Cytotoxicity of TDP-43 Fibrils.
Purvinsh Y et al.
Acs Chemical Neuroscience, 2026
From Evasion to Collapse: The Kinetic Cascade of TDP-43 and the Failure of Proteostasis.
Jamerlan A et al.
International Journal of Molecular Sciences, 2026
Computational Exploration of the Molecular Mechanism of Epigallocatechin Gallate against TDP-43 Aggregation.
Yi W et al.
Journal of Chemical Information and Modeling, 2026
Inhibiting Glycogen Synthase Kinase 3 Suppresses TDP-43-Mediated Neurotoxicity in a Caspase-Dependent Manner.
White MA et al.
Molecular Neurobiology, 2026
Reduction of RAD23A extends lifespan and mitigates pathology in a mouse model of TDP-43 proteinopathy.
Guo X et al.
Nature Communications, 2026
Amyloidogenic oligomers derived from TDP-43 LCD promote the condensation and phosphorylation of TDP-43.
Chen BP et al.
Chemical Science, 2026
Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria.
Keritam O et al.
Journal of Neurology, 2026
Calcineurin depletion coincides with phosphorylated TDP-43 deposition in a mouse model of ALS/FTLD-TDP.
Waldherr SM et al.
Acta Neuropathologica Communications, 2026
A partial deletion of the Tardbp 3'UTR affects TDP-43 regulation and leads to motor dysfunction in mice.
Dinh TTH et al.
Experimental Animals, 2026
Structure, Function, Pathomechanisms and Targeting of TDP-43 in Neurodegeneration.
Zhang X et al.
Brain Research, 2026
TARDBP (TDP-43) Knock-in Zebrafish Display a Late-Onset Motor Phenotype and Loss of Large Spinal Cord Motor Neurons.
Harji ZA et al.
Annals of Neurology, 2026
Reduced cortico-muscular output is associated with intrinsic hypoexcitability and reduced persistent inward currents in motor cortex neurons of TDP-43Q331K ALS mice.
Viteri JA et al.
Neurobiology of Disease, 2026
G-Quadruplexes Abet Neuronal Burnout in ALS and FTD.
Herbert A
Antioxidants (basel, Switzerland), 2025
Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD.
Su J et al.
Cells, 2025
Pharmacological Activation of Mitophagy Confers Neuroprotective Benefits for Amyotrophic Lateral Sclerosis.
Huang S et al.
Aging and Disease, 2025
Genetic spectrum among 2009 Iranian individuals with neuromuscular disorders using next generation sequencing and multiple ligation dependent probe amplification methods.
Molaei N et al.
Scientific Reports, 2025
Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: a focused review for orphan drug (Tofersen).
Kumar A et al.
Orphanet Journal of Rare Diseases, 2025
Serum small non-coding RNA define molecular subtypes in amyotrophic lateral sclerosis.
Baindoor S et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 2025
TRAF6 regulates ubiquitination-independent TDP-43 condensation and related neurodegeneration.
Guo S et al.
Molecular Psychiatry, 2025
Muscle-derived miR-126 regulates TDP-43 axonal local synthesis and NMJ integrity in ALS models.
Ionescu A et al.
Nature Neuroscience, 2025
TDP-43 in Alzheimer's disease: Pathophysiology and therapeutic strategies.
Zhou X et al.
Pharmacological Research, 2025
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases.
Wu G et al.
Translational Neurodegeneration, 2025
Effects of wild-type and mutant TDP-43 on cognitive function and hippocampal neurons in mice.
He P et al.
Brain Research, 2025
Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development.
Al Ojaimi Y et al.
Journal of Neuropathology and Experimental Neurology, 2025
Pathological forms of TDP-43 in amyotrophic lateral sclerosis (ALS) promote aberrant telomere elongation.
Konopka A et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2025
Genetic architecture of amyotrophic lateral sclerosis: a comprehensive review.
Yuan L et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao, 2025
Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS.
Poulin-Brière A et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics, 2025
A Putative Role for the BCL2 Family of Proteins in the Pathophysiology of ALS.
Nuovo GJ et al.
Cns & Neurological Disorders Drug Targets, 2025
A cellular model of TDP-43 induces phosphorylated TDP-43 aggregation with distinct changes in solubility and autophagy dysregulation.
Dopler MB et al.
The Febs Journal, 2025
Cryptic Splicing of GAP43 mRNA is a Novel Hallmark of TDP-43-Associated ALS and AD.
Yang M et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2025
Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection.
Verdés S et al.
Human Gene Therapy, 2025
A Slower-Progressing TDP-43 rNLS8 Mouse Model for ALS: Implications for Preclinical and Mechanistic Studies.
Jagaraj CJ et al.
Neuromolecular Medicine, 2025
Aggregation of TDP-43307-319: A Dual Pathway to Forming Cylindrins and Fibrils and a Contribution to the Etiology of Amyotrophic Lateral Sclerosis.
Jin Y et al.
The Journal of Physical Chemistry. B, 2025
Transcriptome-based screening in TARDBP/TDP-43 knock-in motor neurons identifies the NEDD8-activating enzyme inhibitor MLN4924.
Lépine S et al.
Scientific Reports, 2025
The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis.
Nógrádi B et al.
Nature Communications, 2025
A depression-associated protein FKBP5 functions in autophagy initiation through scaffolding the VPS34 complex.
Park H et al.
Molecular Neurobiology, 2025
TDP-43 mutants with different aggregation properties exhibit distinct toxicity, axonal transport, and secretion for disease progression in a mouse ALS/FTLD model.
Mori H et al.
Neurobiology of Disease, 2025
Fluorescence Lifetime-Based FRET Biosensors for Monitoring N Terminal Domain-Dependent Interactions of TDP-43 in Living Cells: A Novel Approach for ALS and FTD Drug Discovery.
Nathan Kochen N et al.
Acs Chemical Neuroscience, 2025
Myopathic aggregation-prone variants in the TDP-43 prion-like domain: genetics paving the way.
Ervilha Pereira P et al.
Brain : a Journal of Neurology, 2025
Challenges of modelling TDP-43 pathology in mice.
Armas JMB et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society, 2025
Inhibiting glycogen synthase kinase 3 suppresses TDP-43-mediated neurotoxicity in a caspase-dependent manner.
White MA et al.
Research Square, 2025
Exploring Protein Misfolding in Amyotrophic Lateral Sclerosis: Structural and Functional Insights.
Ivantsik O et al.
Biomedicines, 2025
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration.
Kellett EA et al.
Molecular Neurodegeneration, 2025
Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses.
Verde EM et al.
Cells, 2025
Aggregates associated with amyotrophic lateral sclerosis sequester the actin-binding protein profilin 2.
Kubinski S et al.
Human Molecular Genetics, 2025
Recent advances in CDC7 kinase inhibitors: Novel strategies for the treatment of cancers and neurodegenerative diseases.
Peng X et al.
European Journal of Medicinal Chemistry, 2025